Roche wins Japan approval for personalized cancer drug Rozlytrek

22:29 EDT 17 Jun 2019 | Reuters

Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world's biggest maker of cancer drugs pushes ahead in personalized medicines that require a biomarker test to identify prospective patients.

Original Article: Roche wins Japan approval for personalized cancer drug Rozlytrek

More From BioPortfolio on "Roche wins Japan approval for personalized cancer drug Rozlytrek"